Jan de Kraker

8.3k total citations
147 papers, 5.6k citations indexed

About

Jan de Kraker is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Neurology. According to data from OpenAlex, Jan de Kraker has authored 147 papers receiving a total of 5.6k indexed citations (citations by other indexed papers that have themselves been cited), including 82 papers in Molecular Biology, 45 papers in Pulmonary and Respiratory Medicine and 39 papers in Neurology. Recurrent topics in Jan de Kraker's work include Renal and related cancers (74 papers), Neuroblastoma Research and Treatments (38 papers) and Renal cell carcinoma treatment (31 papers). Jan de Kraker is often cited by papers focused on Renal and related cancers (74 papers), Neuroblastoma Research and Treatments (38 papers) and Renal cell carcinoma treatment (31 papers). Jan de Kraker collaborates with scholars based in Netherlands, France and United Kingdom. Jan de Kraker's co-authors include P.A. Voûte, Bengt Sandstedt, Rosalyn Slater, Harm van Tinteren, Huib N. Caron, Norbert Graf, Gordan Vujanić, Cornelis A. Hoefnagel, Jan Godziński and Ivo Leuschner and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Jan de Kraker

145 papers receiving 5.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jan de Kraker Netherlands 43 3.4k 1.9k 1.5k 1.4k 689 147 5.6k
Christophe Bergeron France 44 2.1k 0.6× 2.5k 1.3× 1.5k 1.0× 888 0.6× 542 0.8× 174 5.4k
Najat C. Daw United States 40 1.4k 0.4× 2.7k 1.4× 507 0.3× 470 0.3× 509 0.7× 154 4.7k
Hélène Pacquement France 36 748 0.2× 1.4k 0.7× 638 0.4× 899 0.7× 279 0.4× 108 4.1k
H. Jürgens Germany 40 851 0.2× 3.4k 1.8× 719 0.5× 505 0.4× 301 0.4× 138 5.4k
Katherine A. Janeway United States 35 1.5k 0.4× 2.1k 1.1× 762 0.5× 277 0.2× 1.1k 1.7× 148 4.5k
Teresa J. Vietti United States 43 1.4k 0.4× 4.6k 2.4× 1.3k 0.9× 777 0.6× 429 0.6× 149 8.0k
Leo Mascarenhas United States 28 792 0.2× 1.3k 0.7× 452 0.3× 551 0.4× 328 0.5× 149 3.1k
A. Horwich United Kingdom 54 2.5k 0.7× 2.7k 1.4× 1.9k 1.3× 407 0.3× 265 0.4× 186 9.8k
Lingyun Ji United States 34 828 0.2× 720 0.4× 657 0.4× 371 0.3× 481 0.7× 130 3.5k
J. S. Malpas United Kingdom 36 1.4k 0.4× 1.2k 0.6× 479 0.3× 308 0.2× 231 0.3× 109 5.5k

Countries citing papers authored by Jan de Kraker

Since Specialization
Citations

This map shows the geographic impact of Jan de Kraker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan de Kraker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan de Kraker more than expected).

Fields of papers citing papers by Jan de Kraker

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan de Kraker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan de Kraker. The network helps show where Jan de Kraker may publish in the future.

Co-authorship network of co-authors of Jan de Kraker

This figure shows the co-authorship network connecting the top 25 collaborators of Jan de Kraker. A scholar is included among the top collaborators of Jan de Kraker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan de Kraker. Jan de Kraker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pritchard‐Jones, Kathy, Christophe Bergeron, Beatriz de Camargo, et al.. (2015). Omission of doxorubicin from the treatment of stage II–III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial. The Lancet. 386(9999). 1156–1164. 129 indexed citations
2.
Schoot, Reineke A., et al.. (2013). The role of 131I-metaiodobenzylguanidine (MIBG) therapy in unresectable and compromising localised neuroblastoma. European Journal of Nuclear Medicine and Molecular Imaging. 40(10). 1516–1522. 7 indexed citations
3.
Graf, Norbert, Harm van Tinteren, Christophe Bergeron, et al.. (2012). Characteristics and outcome of stage II and III non-anaplastic Wilms’ tumour treated according to the SIOP trial and study 93-01. European Journal of Cancer. 48(17). 3240–3248. 61 indexed citations
4.
Pritchard‐Jones, Kathy, Norbert Graf, Christophe Bergeron, et al.. (2011). Doxorubicin can be safely omitted from the treatment of stage II/III, intermediate risk histology wilms tumour: results of the siop wt 2001 randomised trial [Abstract]. ORCA Online Research @Cardiff (Cardiff University). 1 indexed citations
5.
Graf, Norbert, Harm van Tinteren, Kathy Pritchard‐Jones, et al.. (2011). Is the absolute blastema volume after preoperative chemotherapy in nephroblastoma relevant for prognosis? [Abstract]. ORCA Online Research @Cardiff (Cardiff University). 4 indexed citations
6.
Kraker, Jan de, et al.. (2008). Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age. European Journal of Cancer. 44(4). 551–556. 87 indexed citations
7.
Bramer, Jos A. M., et al.. (2004). Colour Doppler ultrasound predicts chemotherapy response, but not survival in paediatric osteosarcoma. Pediatric Radiology. 34(8). 614–619. 9 indexed citations
8.
Swart, Joost F., Jan de Kraker, & Nico van der Lely. (2002). Metaiodobenzylguanidine total-body scintigraphy required for revealing occult neuroblastoma in opsoclonus-myoclonus syndrome. European Journal of Pediatrics. 161(5). 255–258. 20 indexed citations
9.
Boccon‐Gibod, Liliane, Annie Rey, Bengt Sandstedt, et al.. (2000). Complete necrosis induced by preoperative chemotherapy in Wilms tumor as an indicator of low risk: Report of the International Society of Paediatric Oncology (SIOP) Nephroblastoma Trial and Study 9. Medical and Pediatric Oncology. 34(3). 183–183. 4 indexed citations
10.
Satgé, Daniel, Annie J. Sasco, Niels Carlsen, et al.. (1998). A lack of neuroblastoma in Down syndrome: a study from 11 European countries.. Data Archiving and Networked Services (DANS). 58(3). 448–52. 70 indexed citations
11.
Sluis, Peter van, Jan de Kraker, J.P.M. Bökkerink, et al.. (1997). A constitutional balanced 1;17 neuroblastoma translocation. European Journal of Cancer. 33(12). 2136–2136. 1 indexed citations
12.
Burgers, J. M. V., Foppe Oldenburger, Jan de Kraker, et al.. (1997). Ewing’s sarcoma of the pelvis: changes over 25 years in treatment and results. European Journal of Cancer. 33(14). 2360–2367. 28 indexed citations
13.
Staalman, C. R., et al.. (1997). Diagnostic imaging in abdominal neuroblastoma: Is there a complementary role of MIBG-scintigraphy and ultrasonography?. European Journal of Pediatrics. 156(8). 610–615. 4 indexed citations
14.
Hoefnagel, C.A., Jan de Kraker, R.A. Valdés Olmos, & P.A. Voûte. (1995). [131I]MIBG as a first line treatment in advanced neuroblastoma.. PubMed. 39(4 Suppl 1). 61–4. 16 indexed citations
15.
Caron, Hubert, et al.. (1992). Hyperaminoaciduria identifies patients at risk of developing renal tubular toxicity associated with ifosfamide and platinate containing regimens. Medical and Pediatric Oncology. 20(1). 42–47. 38 indexed citations
16.
Kraker, Jan de, Cornelis A. Hoefnagel, & P.A. Voûte. (1991). 131I-Rose Bengal therapy in hepatoblastoma patients. European Journal of Cancer and Clinical Oncology. 27(5). 613–615. 10 indexed citations
17.
Kraker, Jan de, J Lemerle, P.A. Voûte, et al.. (1990). Wilm's tumor with pulmonary metastases at diagnosis: the significance of primary chemotherapy. International Society of Pediatric Oncology Nephroblastoma Trial and Study Committee.. Journal of Clinical Oncology. 8(7). 1187–1190. 54 indexed citations
18.
Hoefnagel, C.A., P.A. Voûte, Jan de Kraker, et al.. (1988). Side effects of I-131-MIBG therapy of neural crest tumors. Australian and New Zealand Journal of Medicine. 18(3). 504. 1 indexed citations
19.
Hoefnagel, Cornelis A., P.A. Voûte, Jan de Kraker, & H.R. Marcuse. (1987). Radionuclide diagnosis and therapy of neural crest tumors using iodine-131 metaiodobenzylguanidine.. PubMed. 28(3). 308–14. 163 indexed citations
20.
Marion, J., M F Tournade, Pierre Bey, et al.. (1986). Abdominal recurrences in Wilms' tumours: A report from the SIOP Wilms' tumour trials and studies. Radiotherapy and Oncology. 5(3). 175–182. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christophe Bergeron Breakdown of academic impact, for papers by Najat C. Daw Breakdown of academic impact, for papers by Hélène Pacquement Breakdown of academic impact, for papers by H. Jürgens Breakdown of academic impact, for papers by Katherine A. Janeway Breakdown of academic impact, for papers by Teresa J. Vietti Breakdown of academic impact, for papers by Leo Mascarenhas Breakdown of academic impact, for papers by A. Horwich Breakdown of academic impact, for papers by Lingyun Ji Breakdown of academic impact, for papers by J. S. Malpas
Rankless by CCL
2026